Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.55 Average Target Price from Analysts

Lucid Diagnostics Inc. (NASDAQ:LUCD - Get Free Report) has earned an average recommendation of "Buy" from the five analysts that are presently covering the company, MarketBeat reports. Four analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $3.55.

LUCD has been the subject of a number of recent analyst reports. Needham & Company LLC restated a "buy" rating and set a $3.00 price target on shares of Lucid Diagnostics in a report on Wednesday, May 14th. BTIG Research set a $2.00 target price on Lucid Diagnostics in a research note on Tuesday, March 25th. Ascendiant Capital Markets upped their price target on Lucid Diagnostics from $7.50 to $7.75 and gave the company a "buy" rating in a research note on Friday, June 6th. Cantor Fitzgerald reissued an "overweight" rating and set a $2.00 price objective on shares of Lucid Diagnostics in a research report on Thursday, May 15th. Finally, Wall Street Zen lowered shares of Lucid Diagnostics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd.

Institutional Investors Weigh In On Lucid Diagnostics

Institutional investors have recently modified their holdings of the company. LPL Financial LLC boosted its holdings in Lucid Diagnostics by 29.1% during the 4th quarter. LPL Financial LLC now owns 53,391 shares of the company's stock valued at $44,000 after acquiring an additional 12,035 shares during the period. Berkshire Asset Management LLC PA purchased a new position in shares of Lucid Diagnostics in the first quarter valued at approximately $30,000. Goldman Sachs Group Inc. grew its holdings in shares of Lucid Diagnostics by 35.7% in the first quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company's stock valued at $129,000 after purchasing an additional 22,727 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in Lucid Diagnostics during the 1st quarter worth approximately $37,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Lucid Diagnostics during the first quarter worth $39,000. 74.01% of the stock is owned by institutional investors and hedge funds.

Lucid Diagnostics Price Performance

Shares of LUCD traded up $0.03 during mid-day trading on Monday, reaching $1.26. The stock had a trading volume of 752,717 shares, compared to its average volume of 591,558. Lucid Diagnostics has a 52-week low of $0.68 and a 52-week high of $1.80. The firm has a market cap of $136.32 million, a price-to-earnings ratio of -0.94 and a beta of 1.31. The business's fifty day moving average is $1.28 and its 200 day moving average is $1.18.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.